KMCRIC

Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection.

Ouwehand AC, Ten Bruggencate SJ, Schonewille AJ, Alhoniemi E, Forssten SD, Bovee-Oudenhoven IM.

Br J Nutr.

2013

111(3)

465-73.

10.1017/S0007114513002547.

23930950

http://www.ncbi.nlm.nih.gov/pubmed/23930950

Abdominal Pain/etiology
Abdominal Pain/prevention & control
Adult
Diarrhea/etiology
Diarrhea/prevention & control
Disease Resistance*
Double-Blind Method
Enterotoxigenic Escherichia coli/immunology*
Escherichia coli Infections/immunology
Escherichia coli Infections/microbiology
Escherichia coli Infections/physiopathology
Escherichia coli Infections/prevention & control*
Escherichia coli Vaccines/adverse effects
Escherichia coli Vaccines/immunology
Feces/chemistry
Feces/microbiology
Foodborne Diseases/immunology
Foodborne Diseases/microbiology
Foodborne Diseases/physiopathology
Foodborne Diseases/prevention & control*
Gastroenteritis/immunology
Gastroenteritis/microbiology
Gastroenteritis/physiopathology
Gastroenteritis/prevention & control*
Humans
Immunoglobulin A/analysis
Immunoglobulin M/analysis
Lactobacillus acidophilus/immunology*
Leukocyte L1 Antigen Complex/analysis
Male
Probiotics/adverse effects
Probiotics/therapeutic use*
Severity of Illness Index
Vaccines, Attenuated/adverse effects
Vaccines, Attenuated/immunology
Young Adult

Enterotoxigenic Escherichia coli; Intestinal infection; Lactobacillus acidophilus; Microbiota; Probiotics

장독소생성 대장균; 장 감염; 락토바실러스 아시도필루스; 미생물총; 프로바이오틱스

없음

To assess the effect of Lactobacillus acidophilus (American Type Culture Collection (ATCC) 700396) on enterotoxigenic Escherichia coli (ETEC) infection, in the present study, a parallel, double-blind, placebo-controlled 4-week intervention was performed in healthy males. The subjects largely consumed their habitual diet, but had to abstain from consuming dairy foods generally high in Ca. The subjects were randomised into the L. acidophilus (dose 109 colony-forming units twice daily; n 20) or the placebo (n 19) group. After an adaptation period of 2 weeks, the subjects were orally infected with a live, but attenuated, ETEC vaccine, able to induce mild, short-lived symptoms. Before and after the challenge, the subjects recorded stool consistency, bowel habits, and frequency and severity of gastrointestinal complaints. The ETEC challenge led to a significant increase in faecal output on the 2nd day and a concomitant increase in Bristol stool scale scores. Likewise, abdominal pain, bloating, flatulence, fever, headache and nausea peaked 1 d after the oral challenge. The concentrations of faecal calprotectin and IgA peaked 2 d after and that of serum IgM peaked 9 and 15 d after the oral challenge. The concentrations of serum IgA and IgG were unaffected. The ETEC challenge led to a reduction in the number of Bacteroides-Prevotella, Bifidobacterium, Clostridium cluster XIVab and total faecal bacteria. Probiotic treatment was associated with a larger increase in Bristol stool scale scores and more fever, headache and nausea after the ETEC challenge compared with the placebo treatment. These differences were, however, small and with substantial variation within the groups. Oral application of an attenuated live ETEC vaccine provides a useful model for food-borne infections. Supplementation with L. acidophilus ATCC 700396, however, was ineffective in reducing ETEC infection symptoms in healthy men.

영어